Duncker Streett Co Inc Lowers stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Duncker Streett Co Inc reduced its stake in Thermo Fisher Scientific by 3.5% during the most recent quarter end. The investment management company now holds a total of 32,276 shares of Thermo Fisher Scientific which is valued at $4,655,813 after selling 1,171 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Apr 25, 2016.Thermo Fisher Scientific makes up approximately 1.71% of Duncker Streett Co Inc’s portfolio.

Thermo Fisher Scientific opened for trading at $145.01 and hit $146.7699 on the upside on Monday, eventually ending the session at $146.5, with a gain of 1.56% or 2.25 points. The heightened volatility saw the trading volume jump to 15,37,092 shares. Company has a market cap of $58,052 M.

Other Hedge Funds, Including , Hudson Valley Investment Advisors Inc Adv boosted its stake in TMO in the latest quarter, The investment management firm added 740 additional shares and now holds a total of 42,431 shares of Thermo Fisher Scientific which is valued at $6,120,672. Thermo Fisher Scientific makes up approx 1.97% of Hudson Valley Investment Advisors Inc Adv’s portfolio.Trust Co Of Oklahoma boosted its stake in TMO in the latest quarter, The investment management firm added 340 additional shares and now holds a total of 15,279 shares of Thermo Fisher Scientific which is valued at $2,243,721. Thermo Fisher Scientific makes up approx 1.22% of Trust Co Of Oklahoma’s portfolio. Oliver Luxxe Assets sold out all of its stake in TMO during the most recent quarter. The investment firm sold 1,614 shares of TMO which is valued $237,016.Simplex Trading reduced its stake in TMO by selling 7,669 shares or 47.25% in the most recent quarter. The Hedge Fund company now holds 8,562 shares of TMO which is valued at $1,244,401. Thermo Fisher Scientific makes up approx 0.19% of Simplex Trading’s portfolio.

On the company’s financial health, Thermo Fisher Scientific reported $1.80 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.74. The company had revenue of $4294.80 million for the quarter, compared to analysts expectations of $4113.28 million. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.63 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Thermo Fisher Scientific was Downgraded by Jefferies to ” Hold” on Apr 29, 2016. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .Company shares were Reiterated by Topeka Capital Markets on Mar 2, 2016 to “Buy”, Firm has raised the Price Target to $ 155 from a previous price target of $145 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.